CS 560
Latest Information Update: 01 Dec 2000
Price :
$50 *
At a glance
- Originator Hayashibara; Sankyo
- Class
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypersensitivity
Most Recent Events
- 01 Dec 2000 Discontinued-III for Allergy in Japan (Injection)
- 27 Apr 1999 New profile
- 27 Apr 1999 Phase-III clinical trials for Allergy in Japan (Injection)